Study identifier:BY9010/M1-131
ClinicalTrials.gov identifier:NCT00163345
EudraCT identifier:N/A
CTIS identifier:N/A
Evaluation of parameters of the small airways and their changes under treatment with ciclesonide (320 mcg once daily) versus placebo in patients with asthma
asthma
Phase 3
No
Ciclesonide
All
20
Interventional
18 Years - 60 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Dec 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|